Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Kidney and Transplant

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 100%Moderate 0 · 0%High 0 · 0%

Adverse events: RBC transfusions · anaemia in predialysis patients

Epoetin alfa every four weeks showed no clear difference in adverse events: RBC transfusions compared with with every two weeks (low certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 1.26 [0.53, 2.98]
2 studies · 470 participants
Low

Adverse events: RBC transfusions · anaemia in predialysis patients

Epoetin theta showed no clear difference in adverse events: RBC transfusions compared with epoetin beta (low certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 1.48 [0.06, 36.1]
1 study · 288 participants
Low

Adverse events: RBC transfusions · anaemia in predialysis patients

Epoetin alpha every 2 weeks showed no clear difference in adverse events: RBC transfusions compared with to weekly (low certainty).

1 finding from 1 review

Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
RR 1.56 [0.71, 3.45]
3 studies · 580 participants
Low